**Supplementary Table S6**

Supplementary Table S10: Interaction analysis between time and frailty status for PBMC subsets (major subsets, CD4 subsets, CD8 subsets, Tregs, and T-cell activation status) and plasma immune response and checkpoint markers. A change score was calculated between patients’ values at three months and baseline (positive values indicating increase). The difference in change score was tested using a Mann-Whitney U test. The number of measurements (N), median, interquartile range (IQR), raw P-values, and FDR-corrected P-values are reported. The P-values below the significance threshold of 5% are indicated in bold italics. FDR: false discovery rate; MFI: mean fluorescence intensity.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Biomarker** | **Fit** | | **Frail** | | ***P*-values** | |
| **N** | **Median [IQR]** | **N** | **Median [IQR]** | **Raw** | **FDR** |
| **PBMC - Major Subsets** |  |  |  |  |  |  |
| Viable cells (% of total cells) | 8 | -0.01 [-0.08;2.39] | 12 | 0.35 [-0.04;1.02] | 0.729 | 0.937 |
| Viable lymphocytes (% of total lymphocytes) | 8 | 0.23 [-0.45;0.91] | 12 | 0.99 [0.30;2.01] | 0.263 | 0.527 |
| Total T-cells (% of viable lymphocytes) | 8 | 3.81 [-2.26;6.06] | 12 | -0.85 [-9.24;1.74] | 0.203 | 0.527 |
| Total T-cells (% of viable cells) | 8 | 2.28 [-0.87;5.90] | 12 | -3.07 [-5.87;4.56] | 0.263 | 0.527 |
| CD4+ T-cells (% of viable lymphocytes) | 8 | 1.51 [-0.63;8.54] | 12 | -1.37 [-7.94;3.19] | 0.298 | 0.536 |
| CD8+ T-cells (% of viable lymphocytes) | 8 | -2.24 [-4.90;-0.20] | 12 | -0.67 [-2.97;0.63] | 0.375 | 0.614 |
| CD4/CD8 ratio (% CD4/CD8 ratio) | 8 | 0.94 [0.01;1.93] | 12 | 0.09 [-1.38;1.46] | 0.263 | 0.527 |
| NK/T-cells (% of viable cells) | 8 | -0.35 [-1.48;0.61] | 12 | -0.03 [-0.29;1.33] | 0.418 | 0.627 |
| Total NK cells (% of viable cells) | 8 | -1.02 [-2.55;2.26] | 12 | 5.07 [0.37;7.44] | 0.114 | 0.527 |
| CD56 bright CD16- (% of total NK cells) | 8 | -0.32 [-0.70;0.93] | 12 | 1.73 [-2.36;5.06] | 0.512 | 0.709 |
| CD56 dim CD16+ (% of total NK cells) | 8 | -9.64 [-16.30;-2.25] | 12 | 10.79 [2.18;22.49] | ***0.049*** | 0.442 |
| Total B-cells (% of viable cells) | 8 | -0.98 [-1.52;1.96] | 12 | 0.76 [-2.47;4.11] | 0.969 | 0.969 |
| Naive B-cells (% of total B-cells) | 8 | 9.37 [2.97;11.87] | 12 | 9.04 [2.03;14.08] | 0.847 | 0.953 |
| Memory B-cells (% of total B-cells) | 8 | -9.25 [-10.63;-3.24] | 12 | -8.87 [-13.01;-2.05] | 0.908 | 0.961 |
| Total monocytes (% of viable cells) | 8 | -2.59 [-5.57;2.52] | 12 | -2.22 [-10.92;2.83] | 0.787 | 0.945 |
| Non-classical monocytes (% of total monocytes) | 8 | 5.39 [3.29;9.00] | 12 | -0.42 [-5.55;2.41] | ***0.010*** | 0.176 |
| Intermediate monocytes (% of total monocytes) | 8 | 4.04 [2.26;5.38] | 12 | 1.95 [-0.32;4.61] | 0.203 | 0.527 |
| Classical monocytes (% of total monocytes) | 8 | -10.08 [-16.99;-6.40] | 12 | -0.89 [-11.98;6.74] | 0.203 | 0.527 |
| **PBMC - CD4 Subsets** |  |  |  |  |  |  |
| Naïve CD4+ (% of CD4+ T-cells) | 8 | 2.82 [-1.65;14.32] | 12 | 7.13 [3.12;11.87] | 0.512 | 0.925 |
| CD27 expression in Naïve CD4+ (MFI) | 8 | 339.50 [94.00;481.00] | 12 | 196.00 [34.00;888.00] | 0.787 | 0.932 |
| CD28 expression in Naïve CD4+ (MFI) | 8 | 60.00 [-34.00;114.00] | 12 | 105.00 [-3.50;214.50] | 0.487 | 0.925 |
| Naïve CD4+ CD27+ CD28+ (% of Naïve CD4+ T-cells) | 8 | 1.10 [0.71;8.12] | 12 | 3.88 [1.58;13.85] | 0.464 | 0.925 |
| CD27 expression in Naïve CD4+ CD27+CD28+ (MFI) | 8 | 317.00 [88.00;397.50] | 12 | 180.00 [27.00;729.50] | 1.000 | 1.000 |
| CD28 expression in Naïve CD4+ CD27+CD28+ (MFI) | 8 | 48.50 [-29.00;102.50] | 12 | 88.00 [-3.00;182.50] | 0.375 | 0.925 |
| Naïve CD4+ CD57+ (% of Naïve CD4+ T-cells) | 8 | 0.10 [-1.40;3.47] | 12 | -0.34 [-1.16;0.27] | 0.563 | 0.925 |
| CM CD4+ (% of CD4+ T-cells) | 8 | -0.83 [-10.94;-0.16] | 12 | -5.08 [-10.21;-0.68] | 0.671 | 0.925 |
| CD27 expression in CM CD4+ (MFI) | 8 | 322.00 [96.00;483.00] | 11 | 176.00 [92.00;743.00] | 0.837 | 0.932 |
| CD28 expression in CM CD4+ (MFI) | 8 | 91.50 [-74.50;177.00] | 12 | 134.00 [12.50;280.00] | 0.335 | 0.925 |
| CM CD4+ CD27+ CD28+ (% of CM CD4+ T-cells) | 8 | 4.08 [2.21;12.56] | 12 | 10.13 [5.46;15.48] | 0.154 | 0.925 |
| CD27 expression in CM CD4+ CD27+CD28+ (MFI) | 8 | 262.50 [72.50;407.50] | 12 | 145.50 [60.50;691.00] | 0.847 | 0.932 |
| CD28 expression in CM CD4+ CD27+CD28+ (MFI) | 8 | 70.00 [-60.00;180.00] | 12 | 95.50 [13.00;249.00] | 0.464 | 0.925 |
| CM CD4+ CD57+ (% of CM CD4+ T-cells) | 8 | 0.38 [-0.71;0.56] | 12 | -0.41 [-1.16;0.17] | 0.335 | 0.925 |
| EM CD4+ (% of CD4+ T-cells) | 8 | 0.50 [-3.42;2.34] | 12 | -1.94 [-3.41;0.13] | 0.375 | 0.925 |
| CD27 expression in EM CD4+ (MFI) | 8 | 248.00 [86.50;359.50] | 11 | 172.00 [-74.00;254.00] | 0.386 | 0.925 |
| CD28 expression in EM CD4+ (MFI) | 8 | 165.00 [-17.00;226.50] | 12 | 159.50 [-32.00;226.00] | 0.969 | 1.000 |
| EM CD4+ CD27+ CD28+(% of EM CD4+ T-cells) | 8 | 9.65 [3.73;18.21] | 12 | 7.90 [2.71;15.97] | 0.671 | 0.925 |
| CD27 expression in EM CD4+ CD27+CD28+ (MFI) | 8 | 252.00 [100.00;347.50] | 12 | 329.00 [-9.50;456.50] | 0.512 | 0.925 |
| CD28 expression in EM CD4+ CD27+CD28+ (MFI) | 8 | 115.00 [14.00;196.50] | 12 | 189.50 [-60.00;345.50] | 0.418 | 0.925 |
| EM CD4+ CD27+CD28- (% of EM CD4+ T-cells) | 8 | -0.11 [-0.59;0.03] | 12 | -0.01 [-0.20;0.03] | 0.374 | 0.925 |
| EM CD4+ CD27-CD28- (% of EM CD4+ T-cells) | 8 | -0.29 [-2.52;0.54] | 12 | -0.37 [-0.81;1.22] | 0.616 | 0.925 |
| EM CD4+ CD27-CD28+ (% of EM CD4+ T-cells) | 8 | -8.04 [-11.64;-3.94] | 12 | -7.74 [-13.09;2.64] | 1.000 | 1.000 |
| EM CD4+ CD57+ (% of EM CD4+ T-cells) | 8 | 0.04 [-0.30;0.37] | 12 | -0.30 [-4.79;0.44] | 0.418 | 0.925 |
| TEMRA CD4+(% of CD4+ T-cells) | 8 | 0.02 [-0.06;0.04] | 12 | 0.01 [-0.13;0.45] | 0.847 | 0.932 |
| CD27 expression in TEMRA CD4+ (MFI) | 8 | 240.00 [-17.00;351.00] | 9 | 316.00 [192.00;422.00] | 0.361 | 0.925 |
| CD28 expression in TEMRA CD4+ (MFI) | 8 | 234.50 [-6.00;470.00] | 12 | 150.00 [-15.00;330.50] | 0.563 | 0.925 |
| TEMRA CD4+ CD27+CD28+ (% of TERMA CD4+ T-cells) | 8 | 3.68 [-0.08;11.75] | 12 | 11.93 [2.64;20.72] | 0.232 | 0.925 |
| CD27 expression in TEMRA CD4+ CD27+CD28+ (MFI) | 8 | 278.00 [107.00;393.00] | 12 | 321.00 [110.00;467.50] | 0.729 | 0.925 |
| CD28 expression in TEMRA CD4+ CD27+CD28+ (MFI) | 8 | 182.00 [54.50;488.50] | 12 | 95.50 [46.50;452.50] | 0.729 | 0.925 |
| TEMRA CD4+ CD27+CD28- (% of TEMRA CD4+ T-cells) | 8 | -1.46 [-4.93;0.50] | 12 | 0.07 [-0.38;5.68] | 0.082 | 0.925 |
| TEMRA CD4+ CD27-CD28- (% of TEMRA CD4+ T-cells) | 8 | -2.13 [-5.89;0.05] | 12 | -3.71 [-12.99;-0.57] | 0.464 | 0.925 |
| TEMRA CD4+ CD57+ (% of TEMRA CD4+ T-cells) | 8 | -2.48 [-14.55;8.90] | 12 | -1.31 [-15.41;5.08] | 0.729 | 0.925 |
| **PBMC - CD8 Subsets** |  |  |  |  |  |  |
| Naïve CD8+ (% of CD8+ T-cells) | 8 | 4.66 [1.18;12.36] | 12 | 2.50 [-2.32;8.18] | 0.418 | 0.999 |
| CD27 expression in Naïve CD8+ (MFI) | 8 | 372.00 [70.50;785.00] | 12 | 248.50 [45.50;881.00] | 0.787 | 0.999 |
| CD28 expression in Naïve CD8+ (MFI) | 8 | 27.00 [-36.50;82.00] | 12 | 48.00 [-26.00;112.00] | 0.589 | 0.999 |
| Naïve CD8+ CD27+ CD28+ (% of Naïve CD8+ T-cells) | 8 | 3.48 [1.07;16.91] | 12 | 9.99 [2.78;23.19] | 0.375 | 0.999 |
| CD27 expression in Naïve CD8+ CD27+CD28+ (MFI) | 8 | 342.00 [59.00;657.50] | 12 | 209.00 [64.00;672.50] | 0.908 | 0.999 |
| CD28 expression in Naïve CD8+ CD27+CD28+ (MFI) | 8 | 13.50 [-49.50;76.50] | 12 | 47.50 [-34.00;100.00] | 0.563 | 0.999 |
| Naïve CD8+ CD57+ (% of Naïve CD8+ T-cells) | 8 | 0.00 [-2.94;0.98] | 12 | -0.93 [-2.90;0.26] | 0.671 | 0.999 |
| CM CD8+ (% of CD8+ T-cells) | 8 | 0.74 [-1.55;2.29] | 12 | -5.30 [-9.86;-1.56] | ***0.049*** | 0.999 |
| CD27 expression in CM CD8+ (MFI) | 8 | 263.50 [73.00;488.00] | 12 | 228.50 [46.00;583.00] | 0.908 | 0.999 |
| CD28 expression in CM CD8+ (MFI) | 8 | 40.50 [-43.00;136.00] | 12 | 90.00 [3.50;283.00] | 0.464 | 0.999 |
| CM CD8+ CD27+ CD28+ (% of CM CD8+ T-cells) | 8 | 4.51 [2.42;16.05] | 12 | 13.63 [-0.02;21.95] | 0.464 | 0.999 |
| CD27 expression in CM CD8+ CD27+CD28+ (MFI) | 8 | 234.00 [54.00;368.00] | 12 | 183.00 [47.00;486.00] | 0.729 | 0.999 |
| CD28 expression in CM CD8+ CD27+CD28+ (MFI) | 8 | 32.50 [-53.00;111.50] | 12 | 63.00 [11.50;228.50] | 0.464 | 0.999 |
| CM CD8+ CD57+ (% of CM CD8+ T-cells) | 8 | 1.15 [-3.86;2.83] | 12 | -0.15 [-2.13;2.59] | 0.908 | 0.999 |
| EM CD8+ (% of CD8+ T-cells) | 8 | -3.25 [-4.58;-0.88] | 12 | -0.77 [-2.57;1.39] | 0.097 | 0.999 |
| CD27 expression in EM CD8+ (MFI) | 8 | 79.00 [41.50;265.50] | 12 | 165.00 [20.50;370.00] | 0.512 | 0.999 |
| CD28 expression in EM CD8+ (MFI) | 8 | 55.00 [-43.50;130.50] | 12 | 61.50 [-45.50;227.50] | 0.563 | 0.999 |
| EM CD8+ CD27+ CD28+(% of EM CD8+ T-cells) | 8 | 3.24 [1.81;15.12] | 12 | 8.36 [-0.11;19.98] | 0.729 | 0.999 |
| CD27 expression in EM CD8+ CD27+CD28+ (MFI) | 8 | 157.00 [29.50;203.50] | 12 | 56.00 [-21.50;331.00] | 0.969 | 1.000 |
| CD28 expression in EM CD8+ CD27+CD28+ (MFI) | 8 | 30.00 [-34.50;83.50] | 12 | 7.00 [-90.50;199.00] | 0.969 | 1.000 |
| EM CD8+ CD27+CD28- (% of EM CD8+ T-cells) | 8 | 1.89 [-0.38;2.27] | 12 | 0.66 [-0.20;2.34] | 0.847 | 0.999 |
| EM CD8+ CD27-CD28- (% of EM CD8+ T-cells) | 8 | -3.60 [-6.12;3.68] | 12 | -3.90 [-9.66;4.78] | 0.847 | 0.999 |
| EM CD8+ CD27-CD28+ (% of EM CD8+ T-cells) | 8 | -7.79 [-13.54;0.46] | 12 | -8.87 [-15.78;2.93] | 0.787 | 0.999 |
| EM CD8+ CD57+ (% of EM CD8+ T-cells) | 8 | 1.18 [-1.91;3.53] | 12 | -0.40 [-7.18;4.76] | 0.847 | 0.999 |
| TEMRA CD8+(% of CD8+ T-cells) | 8 | -1.45 [-6.26;0.94] | 12 | 1.61 [-1.30;6.37] | 0.133 | 0.999 |
| CD27 expression in TEMRA CD8+ (MFI) | 8 | 17.50 [-23.50;176.00] | 12 | 110.00 [-5.00;158.00] | 0.487 | 0.999 |
| CD28 expression in TEMRA CD8+ (MFI) | 8 | 29.50 [-16.00;52.00] | 12 | -1.50 [-35.00;55.50] | 0.787 | 0.999 |
| TEMRA CD8+ CD27+CD28+ (% of TERMA CD8+ T-cells) | 8 | 0.94 [-1.30;6.69] | 12 | 3.14 [-0.43;5.13] | 0.847 | 0.999 |
| CD27 expression in TEMRA CD8+ CD27+CD28+ (MFI) | 8 | 125.50 [-32.50;204.00] | 11 | 41.00 [-109.00;361.00] | 0.710 | 0.999 |
| CD28 expression in TEMRA CD8+ CD27+CD28+ (MFI) | 8 | 29.00 [-6.50;84.50] | 11 | 14.00 [-62.00;323.00] | 1.000 | 1.000 |
| TEMRA CD8+ CD27+CD28- (% of TEMRA CD8+ T-cells) | 8 | 0.42 [-0.55;3.01] | 12 | 1.80 [1.06;2.59] | 0.298 | 0.999 |
| TEMRA CD8+ CD27-CD28- (% of TEMRA CD8+ T-cells) | 8 | -2.15 [-8.27;2.86] | 12 | -1.20 [-6.26;4.30] | 0.671 | 0.999 |
| TEMRA CD8+ CD57+ (% of TEMRA CD8+ T-cells) | 8 | 0.64 [-1.76;4.40] | 12 | 1.52 [-3.25;9.60] | 0.847 | 0.999 |
| **PBMC - Tregs** |  |  |  |  |  |  |
| Total Treg (% of CD4+ T-cells) | 8 | -0.10 [-0.50;0.14] | 12 | -0.95 [-1.85;0.12] | 0.375 | 0.766 |
| CD25 expression in Total Treg (MFI) | 8 | 196.50 [-57.00;1125.50] | 12 | 229.50 [-42.50;767.00] | 0.787 | 0.932 |
| CTLA-4 expression in Total Treg (MFI) | 8 | 35.50 [5.00;64.00] | 12 | -6.00 [-32.50;43.00] | 0.165 | 0.766 |
| Naïve Treg (% of total Tregs) | 8 | 3.12 [-0.51;3.84] | 12 | 4.84 [1.84;8.89] | 0.298 | 0.766 |
| CD25 expression of Naïve Treg (MFI) | 8 | 355.50 [44.00;672.00] | 12 | 322.50 [-174.00;951.50] | 0.616 | 0.932 |
| CTLA-4 expression of Naïve Treg (MFI) | 8 | 20.00 [4.00;69.00] | 12 | 3.00 [-15.50;34.50] | 0.418 | 0.766 |
| Naïve Treg CTLA-4+ (% of Naïve Tregs) | 8 | 1.74 [-0.49;10.56] | 12 | -0.73 [-16.63;3.83] | 0.232 | 0.766 |
| Memory Treg (% of total Tregs) | 8 | -3.28 [-4.41;-0.12] | 12 | -4.97 [-8.73;-1.76] | 0.263 | 0.766 |
| CD25 expression of Memory Treg (MFI) | 8 | 214.50 [-95.50;1111.00] | 12 | 204.00 [64.00;762.00] | 0.969 | 0.969 |
| CTLA-4 expression of Memory Treg (MFI) | 8 | 18.50 [-7.50;48.00] | 12 | 1.50 [-37.00;46.00] | 0.700 | 0.932 |
| Memory Treg CTLA-4+ (% of Memory Tregs) | 8 | 0.81 [-0.71;5.38] | 12 | 1.08 [-3.34;3.82] | 0.847 | 0.932 |
| **PBMC – T-cell activation status** |  |  |  |  |  |  |
| CD4+ PD1+ (% of CD4+ T-cells) | 8 | -0.31 [-0.81;0.39] | 12 | 0.15 [-0.20;1.47] | 0.298 | 0.794 |
| PD1 expression in CD4+ (MFI) | 8 | 15.00 [-6.00;22.50] | 12 | 16.50 [-33.50;53.50] | 0.847 | 0.884 |
| CD4+ CD69+ (% of CD4+ T-cells) | 8 | -0.32 [-6.04;3.50] | 12 | 0.03 [-4.91;3.84] | 0.729 | 0.884 |
| CD69 expression in CD4+ (MFI) | 8 | -8.50 [-18.50;33.00] | 12 | 13.50 [-4.50;43.50] | 0.375 | 0.836 |
| CD4+ PD1+CD69+ (% of CD4+ T-cells) | 8 | -0.57 [-0.81;0.32] | 12 | 0.03 [-0.09;0.80] | 0.203 | 0.695 |
| CD4+ PD1-CD69- (% of CD4+ T-cells) | 8 | -0.04 [-3.61;6.86] | 12 | -0.10 [-4.21;3.97] | 0.616 | 0.884 |
| CD4+ HLADR+ (% of CD4+ T-cells) | 8 | 4.03 [-1.75;4.49] | 12 | 0.90 [-1.75;5.80] | 0.847 | 0.884 |
| HLADR expression in CD4+ (MFI) | 8 | 35.50 [-36.50;171.50] | 12 | -17.00 [-86.00;35.50] | 0.177 | 0.695 |
| CD4+ CD38+ (% of CD4+ T-cells) | 8 | -0.35 [-3.58;6.10] | 12 | 1.95 [-0.22;8.70] | 0.418 | 0.836 |
| CD38 expression in CD4+ (MFI) | 8 | -48.00 [-85.00;98.00] | 12 | 15.00 [-52.00;109.00] | 0.512 | 0.878 |
| CD4+ HLADR+CD38+ (% of CD4+ T-cells) | 8 | 0.31 [-0.51;1.98] | 12 | 0.85 [0.31;1.81] | 0.418 | 0.836 |
| CD4+ HLADR-CD38- (% of CD4+ T-cells) | 8 | -1.07 [-5.49;2.06] | 12 | -2.68 [-12.19;1.44] | 0.464 | 0.856 |
| CD8+ PD1+ (% of CD8+ T-cells) | 8 | 1.28 [-9.20;8.50] | 12 | 0.07 [-0.99;8.24] | 0.729 | 0.884 |
| PD1 expression in CD8+ (MFI) | 8 | -15.50 [-37.00;-5.00] | 12 | -4.50 [-24.50;56.50] | 0.153 | 0.695 |
| CD8+ CD69+ (% of CD8+ T-cells) | 8 | -2.89 [-6.68;-0.49] | 12 | 0.94 [-2.55;8.64] | 0.070 | 0.695 |
| CD69 expression in CD8+ (MFI) | 8 | 60.00 [-209.50;133.50] | 12 | 27.50 [-0.50;146.50] | 0.729 | 0.884 |
| CD8+ PD1+CD69+ (% of CD8+ T-cells) | 8 | 1.15 [-2.99;2.37] | 12 | 0.06 [-0.48;4.16] | 0.969 | 0.969 |
| CD8+ PD1-CD69- (% of CD8+ T-cells) | 8 | 1.62 [0.36;13.59] | 12 | -1.51 [-10.33;3.14] | 0.232 | 0.695 |
| CD8+ HLADR+ (% of CD8+ T-cells) | 8 | -1.67 [-5.26;5.20] | 12 | 4.14 [1.26;14.62] | 0.083 | 0.695 |
| HLADR expression in CD8+ (MFI) | 8 | 18.50 [-34.00;51.50] | 12 | 36.50 [-66.50;208.00] | 0.758 | 0.884 |
| CD8+ CD38+ (% of CD8+ T-cells) | 8 | 2.53 [-0.90;8.00] | 12 | 1.83 [0.94;7.01] | 0.787 | 0.884 |
| CD38 expression in CD8+ (MFI) | 8 | 39.00 [-20.00;95.00] | 12 | 7.50 [-36.00;82.50] | 0.787 | 0.884 |
| CD8+ HLADR+CD38+ (% of CD8+ T-cells) | 8 | -0.07 [-1.08;3.42] | 12 | 1.91 [0.28;4.75] | 0.203 | 0.695 |
| CD8+ HLADR-CD38- (% of CD8+ T-cells) | 8 | 0.96 [-8.41;4.39] | 12 | -6.17 [-17.26;-3.46] | 0.133 | 0.695 |
| **Plasma - Essential Immune Response** |  |  |  |  |  |  |
| IL-4 (pg/mL) | 8 | 0.29 [-1.15;6.22] | 12 | 0.00 [-0.44;0.50] | 0.560 | 0.840 |
| IL-2 (pg/mL) | 8 | 0.31 [-1.48;7.05] | 12 | -0.15 [-1.83;0.83] | 0.464 | 0.835 |
| CXCL-10 (IP-10) (pg/mL) | 8 | 99.44 [-26.50;259.46] | 12 | 74.28 [11.17;197.84] | 0.908 | 0.969 |
| IL-1 beta (pg/mL) | 8 | 3.19 [-10.07;18.89] | 12 | -3.19 [-8.79;3.59] | 0.487 | 0.835 |
| TNF alpha (pg/mL) | 8 | -1.11 [-3.32;0.15] | 12 | 0.11 [-1.00;1.13] | 0.133 | 0.397 |
| CCL2 (MCP-1) (pg/mL) | 8 | 21.50 [-59.56;132.87] | 12 | 38.48 [-13.15;95.82] | 0.908 | 0.969 |
| IL-17A (pg/mL) | 8 | -1.08 [-10.87;2.35] | 12 | -0.90 [-1.51;0.56] | 0.787 | 0.969 |
| IL-6 (pg/mL) | 8 | -0.57 [-9.71;2.34] | 12 | 1.43 [-0.07;5.02] | 0.097 | 0.397 |
| IL-10 (pg/mL) | 8 | -1.87 [-2.28;-1.21] | 12 | -0.89 [-1.81;0.70] | 0.114 | 0.397 |
| IFN gamma (pg/mL) | 8 | 0.47 [-24.19;2.61] | 12 | 0.00 [-3.44;1.90] | 0.969 | 0.969 |
| IL-12p70 (pg/mL) | 8 | -1.61 [-14.13;4.29] | 12 | 1.30 [-1.48;4.03] | 0.298 | 0.714 |
| CXCL-8 (IL-8) (pg/mL) | 8 | -1.56 [-8.51;-0.44] | 12 | 1.47 [0.51;3.24] | ***0.023*** | 0.274 |
| **Plasma - Immune Checkpoint** |  |  |  |  |  |  |
| sCD25 (IL-2Ra) (pg/mL) | 8 | 142.73 [51.07;345.70] | 12 | 65.99 [-40.75;226.39] | 0.464 | 0.795 |
| 4-1BB (pg/mL) | 8 | -19.40 [-39.76;7.14] | 12 | -4.20 [-17.44;2.91] | 0.464 | 0.795 |
| sCD27 (pg/mL) | 8 | -599.80 [-3829.00;846.70] | 12 | -5006.00 [-17099.00;1198.10] | 0.203 | 0.609 |
| B7.2 (CD86) (pg/mL) | 8 | -143.10 [-203.50;-55.31] | 12 | -108.20 [-134.00;-35.32] | 0.616 | 0.924 |
| Free Active TGF-B1 (pg/mL) | 8 | -14.20 [-18.56;-5.11] | 12 | -8.73 [-11.22;9.84] | 0.133 | 0.609 |
| CTLA-4 (pg/mL) | 8 | -3.70 [-8.00;1.19] | 12 | -2.03 [-4.54;0.70] | 0.787 | 0.990 |
| PD-L1 (pg/mL) | 8 | -50.06 [-106.10;38.33] | 12 | 15.21 [-13.97;40.45] | 0.154 | 0.609 |
| PD-L2 (pg/mL) | 8 | 1297.00 [-126.30;1712.80] | 12 | 495.34 [-276.10;2131.10] | 0.847 | 0.990 |
| PD-1 (pg/mL) | 8 | -26.26 [-100.90;0.81] | 12 | -9.40 [-42.33;2.62] | 0.464 | 0.795 |
| Tim-3 (pg/mL) | 8 | 815.64 [-1557.00;2143.90] | 12 | 93.20 [-4254.00;2849.00] | 0.908 | 0.990 |
| LAG-3 (pg/mL) | 8 | -408.80 [-1412.00;2921.60] | 12 | -347.70 [-593.80;448.45] | 1.000 | 1.000 |
| Gal-9 (pg/mL) | 8 | 12127.00 [2463.40;35168.00] | 12 | 3440.50 [-10789.00;18306.00] | 0.203 | 0.609 |